Back to Search
Start Over
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
- Source :
- European Journal of Cancer, European Journal of Cancer, Elsevier, 2018, 96, pp.17-24. ⟨10.1016/j.ejca.2018.03.015⟩, European Journal of Cancer, 2018, 96, pp.17-24. ⟨10.1016/j.ejca.2018.03.015⟩
- Publication Year :
- 2018
-
Abstract
- Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study aimed to evaluate the independent impact of the year of MBC diagnosis on OS in the Epidemio-Strategy-Medical-Economical (ESME)-MBC cohort.ESME-MBC (NCT03275311) is a French, national, multicentre, observational cohort including 16,702 consecutive newly diagnosed MBC patients (01 January 2008-31 December 2014). Of 16,680 eligible patients, 15,085 had full immunohistochemistry data, allowing classification as hormone receptor-positive and HER2-negative (HR+/HER2-, N = 9907), HER2-positive (HER2+, N = 2861) or triple-negative (HR-/HER2-, N = 2317) subcohorts. Multivariate analyses of OS were conducted among the full ESME cohort and subcohorts.Median OS of the whole cohort was 37.22 months (95% confidence interval [CI], 36.3-38.04). Year of diagnosis was an independent predictor of OS (hazard ratio 0.98 [95% CI, 0.97-1.00], P = .01) together with age, subtype, disease-free interval, visceral metastases and number of organs involved. Median OS of HR+/HER2-, HER2+ and HR-/HER2- subcohorts was, respectively, 42.12 (95% CI, 40.90-43.10), 44.91 (95% CI, 42.51-47.90) and 14.52 (95% CI, 13.70-15.24) months. Year of diagnosis was a strong independent predictor of OS in HER2+ subcohort (hazard ratio 0.91 [95% CI, 0.88-0.94], P .001), but not in HR+/HER2- nor HR-/HER2- subcohorts (hazard ratio 1.00 [95% CI, 0.98-1.01], P = .80 and 1.00 [95% CI, 0.97-1.02], P = .90, respectively).The OS of MBC patients has slightly improved over the past decade. However, this effect is confined to HER2+ cases, highlighting the need of new strategies in the other subtypes.
- Subjects :
- Adult
Cancer Research
medicine.medical_specialty
Multivariate analysis
Time Factors
Receptor, ErbB-2
[SDV.CAN]Life Sciences [q-bio]/Cancer
Breast Neoplasms
Triple Negative Breast Neoplasms
03 medical and health sciences
Young Adult
0302 clinical medicine
Cancer Survivors
Risk Factors
HER2
Internal medicine
polycyclic compounds
Overall survival
Biomarkers, Tumor
Medicine
Humans
030212 general & internal medicine
Neoplasm Metastasis
skin and connective tissue diseases
Aged
Retrospective Studies
Subtypes
Aged, 80 and over
business.industry
Time trends
Hazard ratio
Middle Aged
Metastatic breast cancer
medicine.disease
Confidence interval
3. Good health
Treatment Outcome
Oncology
Receptors, Estrogen
030220 oncology & carcinogenesis
Cohort
Observational study
Female
France
business
Receptors, Progesterone
Subjects
Details
- ISSN :
- 18790852 and 09598049
- Volume :
- 96
- Database :
- OpenAIRE
- Journal :
- European journal of cancer (Oxford, England : 1990)
- Accession number :
- edsair.doi.dedup.....faf28882b44d710d4a307541061e8768